Mesoblast stock trades at 1.25 euros in Tuesday evening session

Mesoblast stock traded at 1.25 euros on Lang & Schwarz at 20:52 CET on Tuesday, November 10, 2026. The evening quote gives investors a current reference for the Australian cell-therapy company, while the next major valuation drivers remain commercial execution and clinical progress.

Ryoncil Supports Commercial Expansion

Mesoblast already generates revenue from Ryoncil, its FDA-approved therapy for pediatric patients with steroid-refractory acute graft-versus-host disease. A FinanzNachrichten report said Ryoncil generated net sales of 28 million US dollars in the quarter ended September 2026, up 44 percent from the comparable period.

The report also cited cash of 99 million US dollars at September 30 and full-year Ryoncil net sales of 115 million US dollars for the first complete financial year after launch. These figures highlight the transition from development-stage biotechnology toward a business with commercial revenue, although continued investment and execution remain material considerations.

Clinical Programs Remain Important

Mesoblast is also studying rexlemestrocel-L for chronic back pain linked to inflammatory changes in the intervertebral discs. According to the report, a pivotal Phase 3 study treated 350 patients, with key results expected in mid-2027. The program is not yet an approved treatment, so clinical and regulatory outcomes remain central to the investment case.

Broader market developments can be followed in Current market reports.

More news and analyses on Mesoblast stock are available on the company topic page.